top of page

Evaluation and research in a common laboratory with Kyoto University.

Our headquarters and research laboratory are located in Kyoto-University Katsura Venture Plaza, where Kyoto University nurtures the creation of new businesses utilizing new ideas/technologies and intellectual properties.


To contribute to the health of people throughout the world through provision of special blood cells produced using regenerative medicine technology.

We produce and provide homogeneous and high precision human blood cells to drastically streamline the evaluation of efficacy and safety of drugs and functional materials, as well as the research of infectious diseases. We also sell evaluation kits and offer various contract evaluation services.


Name of company :
MiCAN Technologies, Inc.

Address :
Kyoto-University Katsura Venture Plaza, 1-36 Goryo-ohara, Nishikyo-ku, Kyoto 615-8245 Japan
TEL: +81-75-381-3008

Representative :
Kazuo Miyazaki, Chief Executive Officer

Established :
July 2016

Capital :

Business lineup :
Provision (sales) of blood cell-like cells for research using regenerative medicine technologies

Evaluation service for pharmaceutical development(contract service) using the above-stated blood cell-like cells

Contract service of various tests using the above-stated blood cell-like cells based on alternative methods to animal testing




Accepted in the Support System for Venture Companies Solving Unmet Medical Needs of the Ministry of Economy, Trade and Industry

2016 July
Foundation(Chuo-ku, Tokyo)

2016 November
Awarded a grand prize of GLOBIS Venture Challenge

2017 Octover
Development of red blood-like cells for research of infectious diseases (Mpv cells, first product) with Kyoto University and Nagasaki University, patent application

2017 December
Started development of myeloid cells for research of viruses (Mylc cells, second product)

2018 February
Established a research and development base at Kyoto-University Katsura Venture Plaza

2018 July
Started release of red blood-like cells (prototype product of Mpv cells)

2018 August
Patent application for myeloid cells for research of viruses (Mylc cells, second product) with Osaka University and Kumamoto University

2018 September
Transferred the Headquarters to Kyoto-University Katsura Venture Plaza

2018 November
Adopted for the Economic Gardening Support Grant supported by Kyoto Industrial Support Organization 21

2018 December
Certified as Management of Wisdom by the Kyoto Chamber of Commerce and Industry

2019 March
Expanded the Headquarters and Laboratory

2019 April
Signed a collaborative research agreement on the development of culture medium with Nissui Pharmaceutical Co., Ltd.

2019 July
Started release of myeloid cells for research of viruses (prototype product)

2019 August
Raised \127,000,000 by allocation of shares to third parties including Osaka University Venture Capital Co., Ltd. (series A)

2020 April
Started collaborative research on corona virus using Mylc cells with Osaka University

2020 June
elected in Support for Improvement Research, Technology Development Project for Measures to Control Viral Infections, by AMED


When I was working in India in my previous career, a number of coworkers succumbed to infectious diseases such as malaria and dengue. Vivax malaria, for which rapid development of new drugs is desired. Dengue fever, for which people are waiting for the development of a vaccine. All research and development of drugs for infectious diseases mediated by blood require a huge number of specific blood cells, and the difficulty in procuring them was the largest cause of the delay in the development of drugs and vaccines.
Thus, I made up my mind to produce and provide the specific blood cells required in large quantity at low price using regenerative medicine technology, a cutting-edge technology of Japan.

After I returned to Japan, my business plan was accepted in the Support System for Venture Companies Solving Unmet Medical Needs of the Ministry of Economy, Trade and Industry in 2015. Then, my business went into full-scale operation and I established my company in 2016. After that, I have received various business support from local governments, associations, and investment institutions and won awards from multiple organizations, and I have been energetically developing blood cell-like cells and providing them to the world with like-minded colleagues and employees.

In 2020, the world is in the midst of the COVID-19 pandemic. In this situation, I sincerely hope that MiCAN’s blood cells can help accelerate the development of new drugs and vaccines.


Chief Executive Officer   
Kazuo Miyazaki

Our Team

Chief Executive Officer

Kazuo Miyazaki

Chief Operating Officer / Chief Financial Officer

Kazuhisa Fushihara

Outside board member

Yasuchika Wakayama

Outside board member

Yuichi Oku

Corporate Auditor

Seiki Mizoguchi

bottom of page